Insider Selling: Shockwave Medical Inc (NASDAQ:SWAV) Director Sells $88,954.00 in Stock

Shockwave Medical Inc (NASDAQ:SWAV) Director Antoine Papiernik sold 1,126 shares of the business’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $79.00, for a total value of $88,954.00. Following the transaction, the director now owns 2,701 shares of the company’s stock, valued at $213,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Antoine Papiernik also recently made the following trade(s):

  • On Monday, October 12th, Antoine Papiernik sold 455 shares of Shockwave Medical stock. The stock was sold at an average price of $79.00, for a total value of $35,945.00.
  • On Monday, October 5th, Antoine Papiernik sold 24,587 shares of Shockwave Medical stock. The stock was sold at an average price of $77.15, for a total value of $1,896,887.05.
  • On Thursday, October 1st, Antoine Papiernik sold 17,744 shares of Shockwave Medical stock. The stock was sold at an average price of $75.32, for a total value of $1,336,478.08.
  • On Monday, September 28th, Antoine Papiernik sold 17,347 shares of Shockwave Medical stock. The stock was sold at an average price of $73.13, for a total value of $1,268,586.11.
  • On Friday, September 18th, Antoine Papiernik sold 12,653 shares of Shockwave Medical stock. The stock was sold at an average price of $73.19, for a total value of $926,073.07.
  • On Monday, September 14th, Antoine Papiernik sold 78,528 shares of Shockwave Medical stock. The stock was sold at an average price of $67.98, for a total value of $5,338,333.44.
  • On Thursday, August 27th, Antoine Papiernik sold 160,440 shares of Shockwave Medical stock. The stock was sold at an average price of $60.43, for a total value of $9,695,389.20.
  • On Tuesday, August 25th, Antoine Papiernik sold 60,657 shares of Shockwave Medical stock. The stock was sold at an average price of $60.05, for a total value of $3,642,452.85.
  • On Thursday, August 20th, Antoine Papiernik sold 33,822 shares of Shockwave Medical stock. The stock was sold at an average price of $60.01, for a total value of $2,029,658.22.
  • On Wednesday, August 12th, Antoine Papiernik sold 1,300 shares of Shockwave Medical stock. The stock was sold at an average price of $55.02, for a total value of $71,526.00.

Shares of NASDAQ:SWAV opened at $78.22 on Friday. The company’s fifty day moving average is $69.97 and its two-hundred day moving average is $50.74. The company has a quick ratio of 13.58, a current ratio of 14.90 and a debt-to-equity ratio of 0.10. Shockwave Medical Inc has a 12-month low of $22.01 and a 12-month high of $79.25. The company has a market cap of $2.66 billion, a P/E ratio of -37.25 and a beta of 0.98.

Shockwave Medical (NASDAQ:SWAV) last announced its earnings results on Tuesday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.06. Shockwave Medical had a negative net margin of 126.34% and a negative return on equity of 35.68%. The company had revenue of $10.30 million for the quarter, compared to the consensus estimate of $8.35 million. During the same period in the previous year, the business earned ($0.38) EPS. The company’s revenue was up 3.0% on a year-over-year basis. Equities research analysts anticipate that Shockwave Medical Inc will post -2.2 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the business. FMR LLC raised its stake in Shockwave Medical by 6.3% during the 2nd quarter. FMR LLC now owns 5,067,390 shares of the company’s stock valued at $240,042,000 after purchasing an additional 302,550 shares during the period. Wellington Management Group LLP raised its stake in Shockwave Medical by 57.0% during the 1st quarter. Wellington Management Group LLP now owns 2,005,121 shares of the company’s stock valued at $66,530,000 after purchasing an additional 727,621 shares during the period. Vanguard Group Inc. grew its holdings in shares of Shockwave Medical by 15.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,002,968 shares of the company’s stock valued at $94,880,000 after acquiring an additional 267,559 shares in the last quarter. Gilder Gagnon Howe & Co. LLC grew its holdings in shares of Shockwave Medical by 34.3% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,914,242 shares of the company’s stock valued at $90,678,000 after acquiring an additional 489,096 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Shockwave Medical by 287.0% during the 1st quarter. Wells Fargo & Company MN now owns 1,143,343 shares of the company’s stock valued at $37,936,000 after acquiring an additional 847,901 shares in the last quarter. 83.75% of the stock is currently owned by institutional investors.

A number of equities research analysts have weighed in on the company. ValuEngine downgraded Shockwave Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 21st. Piper Sandler upped their target price on Shockwave Medical from $76.00 to $86.00 and gave the stock an “overweight” rating in a research report on Friday. Zacks Investment Research raised Shockwave Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 15th. Canaccord Genuity upped their price target on Shockwave Medical from $60.00 to $87.00 and gave the company a “buy” rating in a report on Friday. Finally, Wells Fargo & Company upped their price target on Shockwave Medical from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $58.13.

About Shockwave Medical

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Featured Article: Why are gap-down stocks important?

Insider Buying and Selling by Quarter for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.